

SEND TO:  AcariaHealth  Specialty Pharmacy Provider: \_\_\_\_\_  
Date: \_\_\_\_\_ Date Medication Required: \_\_\_\_\_  
SHIP TO:  Physician  Patient's Home  Other \_\_\_\_\_



Telephone: 855-304-5580 Fax: 855-815-9894

# RSV Prior Authorization Form

Patient Name: \_\_\_\_\_  
Parent/Legal Guardian Name: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_  
State: \_\_\_\_\_ Zip: \_\_\_\_\_ County: \_\_\_\_\_  
Home Phone: \_\_\_\_\_  
Alt Phone: \_\_\_\_\_  
Cell Phone: \_\_\_\_\_  
Date of Birth: \_\_\_\_/\_\_\_\_/\_\_\_\_ Sex:  Male  Female  
Patient Soc. Sec #: XXX-XX-\_\_\_\_ Allergies: \_\_\_\_\_

Physician Name: \_\_\_\_\_  
State Lic # \_\_\_\_\_ DEA # \_\_\_\_\_  
NPI # \_\_\_\_\_ UPIN# \_\_\_\_\_  
Practice Name/Hospital: \_\_\_\_\_  
Specialty: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Physician's Ph: \_\_\_\_\_  
Physician's Fax: \_\_\_\_\_  
Nurse/Key Office Contact: \_\_\_\_\_ Direct Ext: \_\_\_\_\_

## INSURANCE INFORMATION (Complete or Attach Copies of cards)

Primary Insurance: _____	Secondary Insurance: _____	Rx Card (PBM): _____	Cardholder First Name: _____
City: _____ State: _____	City: _____ State: _____	PBM BIN: _____	Last Name: _____
Plan #: _____	Plan #: _____	City: _____ State: _____	Employer: _____
Group #: _____	Group #: _____	Group #: _____	ID #: _____
Phone: (____) _____-_____	Phone: (____) _____-_____	Phone: (____) _____-_____	Group #: _____

## CLINICAL INFORMATION AND MEDICAL ASSESSMENT

### Diagnosis (Required):

- < 24 weeks of gestation (765.21)     27-28 weeks of gestation (765.24)     33-34 weeks of gestation (765.27)     Congenital Heart Disease (Specify ICD-9) \_\_\_\_\_  
 24 weeks of gestation (765.22)     29-30 weeks of gestation (765.25)     35-36 weeks of gestation (765.28)     Chronic Respiratory Disease arising in the perinatal period  
 25-26 weeks of gestation (765.23)     31-32 weeks of gestation (765.26)     37 weeks+ of gestation (765.29)     (CLD) (770.7)  
 Cystic Fibrosis     Congenital Abnormality of Respiratory System (748.3-748.4)  
 Other: \_\_\_\_\_

### Patient Demographics:

Patient's gestational age (Required): \_\_\_\_\_ weeks \_\_\_\_\_ days Birth Weight: \_\_\_\_\_ g/kg/lbs Current Weight: \_\_\_\_\_ g/kg/lbs Date Recorded: \_\_\_\_\_  
Did the patient spend time in the NICU?  Yes  No if yes, please provide NICU name and attach discharge summary: \_\_\_\_\_  
Was this season's first Synagis dose given in the NICU?  Yes  No if yes, please provide date(s): \_\_\_\_\_ Expected date of first/next injection: \_\_\_\_\_

### Patient Evaluation (Check all that apply and submit clinical documentation):

- Hospitalization for RSV infection this season?  
 Diagnosis of hemodynamically significant Congenital Heart Disease (CHD) and < 12 months of age at start of RSV Season and patient has the following conditions  
(Check all that apply):  
 Moderate-Severe Pulmonary Hypertension  
 Cyanotic Heart Disease (if consulted with a pediatric cardiologist)  
 Cyanotic heart disease medications to control CHF (list medications): \_\_\_\_\_ Last Date Received: \_\_\_\_\_ **AND** require cardiac surgical procedures  
 Diagnosis of Chronic Lung Disease\* and less than 12 months at start of RSV Season  
\*CLD is generally defined as: Infants <32 weeks, 0 days: oxygen requirement > 21% for at least the first 28 days of birth.  
CLD is NOT defined as asthma, croup, recurrent upper respiratory infections, chronic bronchitis, bronchiolitis, or a history of a previous RSV infection  
 Diagnosis of Chronic Lung Disease\* and between 12 to less than 24 months at start of RSV Season and receiving treatment of (check all that apply and provide last date received):  
 Supplemental oxygen, Date: \_\_\_\_\_  
 Chronic corticosteroid therapy, Date: \_\_\_\_\_  
 Diuretic therapy, Date: \_\_\_\_\_  
 Diagnosis of Cystic Fibrosis and less than 12 months of age at start of RSV season?  
 Clinical evidence of CLD  
 Nutritional compromise: Explain: \_\_\_\_\_  
 Diagnosis of Cystic Fibrosis and between 12 to less than 24 months of age at start of RSV season  
 Manifestations of severe lung disease (hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or CT that persists when stable)  
 Weight for length less than 10th percentile  
 Is the patient profoundly immunocompromised and less than 24 months at start of RSV season?  
 Yes; Explain: \_\_\_\_\_  No  
 Prematurity gestational age of < 28 weeks, 6 days and less than 12 months at the start of the RSV season  
 Diagnosis of condition that impairs the ability to clear secretions from the upper airway because of ineffective cough AND less than 12 months at the start of RSV season  
 Congenital anomaly that impairs the ability to clear secretions from the upper airway because of ineffective cough  
 Neuromuscular condition  
Please list other medical history and/or risk factors: \_\_\_\_\_

## HOME HEALTH COORDINATION

Please note, separate authorization is required for injection training/home health visit. Call 866-329-4701 ext. 47716 for prior authorization

- Specialty Pharmacy to coordinate injection to coordinate injection training/home health nurse visit as necessary. Please list Agency of choice: \_\_\_\_\_

## PRESCRIPTION INFORMATION

- Synagis® (palivizumab) 50 and/or 100mg vials    Refills \_\_\_\_\_  
Sig: Inject 15mg/kg IM one time per month (Dose to be calculated at time of injection based on patient's current weight)    Qty: QS to achieve 15mg/kg dose  
 Epinephrine 1:1000 amp    Refills \_\_\_\_\_    Sig: Inject 0.01 mg/kg subcutaneously as directed for anaphylaxis  
 Prescriber has counseled parent/guardian on Synagis therapy and the specialty pharmacy may contact parent/guardian

Physician's Signature: \_\_\_\_\_  DAW (Dispense as Written)    Date \_\_\_\_/\_\_\_\_/\_\_\_\_

**IMPORTANT NOTICE:** This facsimile transmission is intended to be delivered only to the name addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the name addressee, except by express authority of sender to the name addressee.